Regulus Therapeutics (NASDAQ: RGLS) has recently received a number of price target changes and ratings updates: 3/25/2024 – Regulus Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock. 3/23/2024 – Regulus Therapeutics is now covered by analysts at StockNews.com. They set a “hold” […]
Analysts’ new coverage for Saturday, March 23rd: StockNews.com started coverage on shares of ATA Creativity Global (NASDAQ:AACG). StockNews.com issued a sell rating on the stock. StockNews.com started coverage on shares of Atlantic American (NASDAQ:AAME). The firm issued a hold rating on the stock. StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS). The firm issued […]
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.27% to 38,873.55 while the NASDAQ rose 0.69% to 16,129.18. The S&P 500 also rose, gaining, 0.52% to 5,144.57.
Regulus Therapeutics (RGLS) Reports Positive Topline Data from the Second Cohort in Phase 1b Trial of RGLS8429 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Regulus Therapeutics (RGLS) Enters $100M Oversubscribed Private Placement streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.